The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
First-in-human study starts include radioligands from Akiram and Philogen.
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
The French group takes a shot at Perspective with its second bet on Orano Med.
The Hutchmed-originated savolitinib moves towards its first US approval.